期刊文献+

非小细胞肺癌靶向治疗研究的分析 被引量:7

Analysis of the targeted therapy of non-small cell lung cancer
原文传递
导出
摘要 目的用文献计量学方法探索非小细胞肺癌(NSCLC)靶向治疗的研究概况和发展趋势。方法在Web of Science数据库中检索1986年至2017年有关NSCLC靶向治疗的文献,分析其年发文量、国家/地区、机构、作者、来源出版物和被引情况。结果共检索得655篇文献,数量有限但是增长迅速。美国的发文量占全球的34%,并有4个机构发文量排进前10;我国发文量占全球的20%,并有4个机构发文量排进前10。全球以美国德州大学MD安德森癌症中心发表文章最多,国内以山东大学发文最多。结论 NSCLC的靶向治疗是全球新兴的研究热点之一,美国在该研究领域具有领先地位,我国发文量较大但仍与国际前沿研究存在一定差距。 Objective To investigate the research status and development trends of the targeted therapy of non-small cell lung cancer( NSCLC) using bibliometric analysis. Methods The literatures on targeted therapy of NSCLC were retrieved from 1986 to 2017 in Web of Science database,and their published years,countries/regions,institutions,authors,journal distribution and cited situation were analyzed.Results A total of 655 literatures concerning targeted therapy of NSCLC were obtained. The number of global published articles is low but growing progressively,34% of which were from USA and 20% of which were from China. In the top 10 institutions,4 institutions were from USA and 4 institutions were from China. The University of Texas MD Anderson Cancer Center from USA issued the largest number of publications in this field globally,and in China,the Shandong University took the first place. Conclusion At present,the targeted therapy of NSCLC is novel and attracting more and more attentions. USA leads the world in this field which followed by China,but there is still a certain gap between them.
作者 樊东升 凌曦 赵志刚 李新刚 FAN Dong- sheng1, LING Xi2, ZHAO Zhi - gang2, LI Xin - gang2(1. Department of Medical Nursing, Jiyuan Vocational and Technical College, Jiyuan 459000, Henan Province, China; 2. Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, Chin)
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2018年第14期1707-1709,共3页 The Chinese Journal of Clinical Pharmacology
关键词 靶向治疗 非小细胞肺癌 文献计量分析 科学引文索引 targeted therapy non -small cell lung cancer bibliometric analysis science citation index
  • 相关文献

参考文献9

二级参考文献86

  • 1张晓彤,李龙芸,王树兰,穆新林,王孟昭.吉非替尼治疗晚期非小细胞肺癌疗效观察[J].中华结核和呼吸杂志,2005,28(3):180-183. 被引量:31
  • 2史庆华.影响因子评价专业学术期刊的科学性与局限性[J].现代情报,2006,26(1):35-36. 被引量:68
  • 3陈冠初.文献计量学与非文献计量学在期刊评价中的应用[J].编辑学报,2006,18(6):472-474. 被引量:20
  • 4Baggstrom M,Socinski MA,Hensing T,et al.Third generation chemotherapy regimens (3GR) improve survival over second generation regimens (2GR) in stage ⅢB/Ⅳ non-small cell lung cancer (NSCLC):a meta-analysis of the published literature.Proc Am Soc Clin Oncol,2002,21:306a.
  • 5Scagliotti GV,De Marinis F,Rinaldi M,et al.Phase Ⅲ randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer.J Clin Oncol,2002,20:4285-4291.
  • 6Delbaldo C.Adding a second or a third drug to a chemotherapy regimen in patients with advanced non-small cell lung carcinoma (NSCLC):a meta-analysis of the lietrature.Proc Am Soc Clin Oncol,2003,22:623.
  • 7Baggstrom M,Socinski MA,Hensing T,et al.Addressing the optimal number of cytotoxic agents in stage ⅢB/Ⅳ non-small cell lung cancer (NSLCC):a meta-analysis of the published literature.Proc Am Soc Clin Oncol,2003,21:306.
  • 8Tiseo M,Boni L,Ardizzoni A.Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer:does cisplatin versus carboplatin make a difference? J Clin Oncol,2005,23:6276-6277.
  • 9Fossella F,Devore R,Kerr R,et al.Randomized phase Ⅲ trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing regimens.The TAX 320 Non-Small Cell Lung Cancer Study Group.J Clin Oncol,2000,18:2354-2360.
  • 10Hanna N,Shepherd FA,Fossella FV,et al.Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with nonsmall-cell lung cancer previously treated with chemotherapy.J Clin Oncol,2004,22:1589-1597.

共引文献314

同被引文献83

引证文献7

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部